After a Series A funding round, many biotech founders suddenly face operational decisions outside their scientific expertise. One of the most common is building the right IT infrastructure for biotech startups without overspending.
We’ve worked with dozens of early-stage life sciences companies across the United States. We see the same pattern almost every time. The founding team is brilliant at biology, chemistry, or device engineering. But when it comes to building an IT foundation, there’s no roadmap. Without a roadmap, companies often invest in the wrong places. Just as often, they overspend on the wrong things.
Building the right IT infrastructure for biotech startups early can prevent expensive mistakes as the company grows. Here’s what we’ve learned actually matters at the Series A stage, and what can wait.
The IT Reality Inside Most Series A Biotech Startups
When we start working with a newly funded biotech, the IT environment typically looks like one of two things: a collection of personal laptops and free-tier cloud tools cobbled together since the founding days, or an attempt at “real” infrastructure that someone built in a hurry when headcount started growing. In either case, the gaps are almost always the same.
Common IT Gaps We See in Series A Biotech Companies
- No unified email or identity management
- No reliable shared file storage
- Inconsistent hardware
- No real IT support
- Security that doesn’t match your ambitions
The good news: life sciences founders and executives almost universally recognize that IT is outside their wheelhouse. Unlike some other startup verticals where a technical co-founder insists on managing IT themselves, biotech leadership tends to be appropriately humble here and open to outside expertise. That openness is the foundation for getting this right.
IT Infrastructure for Biotech Startups: What You Actually Need at Series A
If we were advising a newly funded $5M biotech on where to invest their IT dollar first, here’s the short list:
- A unified identity and email platform. Microsoft 365 is the platform we recommend. It gives you centrally managed email, shared calendaring, and the foundation for access control across every other system.
- Structured cloud file storage with proper permissions. OneDrive and SharePoint are our go-to recommendations here, standardized and centrally managed. The goal is that files live in the company’s environment, not on individual machines or personal accounts.
- A security baseline. At minimum: endpoint protection on every device, multi-factor authentication across all systems, and a basic security awareness standard for your team. This is also the time to start thinking about how your environment will need to evolve toward HIPAA compliance or FDA 21 CFR Part 11 requirements.
- Standardized end-user hardware. Not the most expensive machines available, the right machines for the work being done, purchased through a standard process, managed consistently.
- A real support mechanism. Whether that’s a managed services provider or a dedicated internal resource, your team needs somewhere to go when things break, and things will break. The cost of a scientist losing half a day to a technical problem is far higher than the cost of a support contract.
IT Mistakes Series A Biotech Startups Should Avoid
Here’s where we see early-stage biotech firms get into trouble: executive management gets excited about building a “real” IT environment and starts shopping for enterprise-grade solutions to problems they don’t yet have.
We understand the instinct. You’ve just raised real money. You want to build something that looks and feels like a grown-up company. But in IT, buying for where you hope to be in five years rather than where you are today is one of the most reliable ways to waste capital.
Specific traps we see regularly:
- Expensive enterprise software licenses for tools you won’t fully use. We’ve seen Series A companies purchasing software suites designed for organizations ten times their size. The licenses sit underutilized, the implementation is complex, and the ROI is essentially zero at this stage.
- Premium phone systems. Unless your business model requires sophisticated call center capabilities, a basic cloud-based phone solution is entirely sufficient. The elaborate multi-site VoIP systems can wait until you have multi-site operations that justify them.
- Overbuilt conference rooms. A functional video conferencing setup is essential, a $50,000 AV installation almost certainly isn’t, yet.
- Hardware that exceeds the work being done. There are roles in a biotech company that genuinely require high-powered workstations. There are also many roles that don’t. Buying uniformly premium hardware across the board is a common and costly mistake.
Every IT decision should start with one question. Does this solve a real problem today, or a problem we might have someday?
Why Compliance and Security Planning Matter Early
One thing we’d encourage every Series A biotech to address explicitly, even if the urgency doesn’t feel immediate: what does your compliance roadmap look like, and is your IT architecture pointing in the right direction?
If your work will eventually touch patient data, you’re on a path toward HIPAA. If you’re developing software used in clinical settings, FDA 21 CFR Part 11 will apply. Neither of these requires full compliance at Series A, but both require architectural decisions that are much easier to make now than to retrofit later.
The identity platform you choose, how you structure your file storage and access controls, how you manage audit logging, these all have compliance implications. And increasingly, these same decisions affect your ability to leverage AI tools as your organization grows: siloed, unstructured data environments are the number one reason AI initiatives stall, even at early-stage companies. Getting the architecture right now pays dividends on both fronts. A brief consultation on your compliance and data trajectory is a worthwhile early investment, even if you don’t need to act on everything immediately.
Building the Right IT Foundation
Getting the right IT infrastructure for biotech startups at the Series A stage is not about building a massive enterprise environment. It is about laying the right foundation. The companies we’ve seen navigate this well share a common trait: they made a few focused investments in the right foundation, resisted the temptation to overbuild, and found an IT partner they trusted to tell them the difference. If you’re a life sciences company navigating these decisions, we’d be glad to have the conversation. We’ve been in the room with companies at your stage more times than we can count, and we know what actually matters.
BACS Consulting Group is a managed services provider serving life sciences, financial services, and construction companies across the United States. Explore our life sciences IT case studies.